Show simple item record

dc.contributor.authorSteinbrecher, Astrid
dc.contributor.authorMéplan, Catherine
dc.contributor.authorHesketh, John
dc.contributor.authorSchomburg, Lutz
dc.contributor.authorEndermann, Tobias
dc.contributor.authorJansen, Eugene
dc.contributor.authorAkesson, Bjorn
dc.contributor.authorRohrmann, Sabine
dc.contributor.authorLinseisen, Jakob
dc.date.accessioned2012-07-04T09:32:26Z
dc.date.available2012-07-04T09:32:26Z
dc.date.issued2010-11
dc.identifier.citationCancer Epidemiol. Biomarkers Prev. 2010, 19 (11):2958-2968en_GB
dc.identifier.issn1538-7755
dc.identifier.pmid20852007
dc.identifier.doi10.1158/1055-9965.EPI-10-0364
dc.identifier.urihttp://hdl.handle.net/10146/232071
dc.description.abstractEvidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes.
dc.description.abstractA case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).
dc.description.abstractThe OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98).
dc.description.abstractOur results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.
dc.description.abstractThese findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies.
dc.description.sponsorshipThe following authors have membership on EU NoE, which was instrumental in the initiation of the study: J. Linseisen, S. Rohrmann (ECNIS), J. Hesketh (NuGO), and B. Åkesson (NuGO, ECNIS).en_GB
dc.language.isoenen
dc.relation.urlhttp://cebp.aacrjournals.org/content/19/11/2958.longen_GB
dc.rightsArchived with thanks to Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncologyen_GB
dc.subjectProstate canceren_GB
dc.subjectCancer risken_GB
dc.subjectSeleniumen_GB
dc.subjectSelenoproteinsen_GB
dc.subjectGenotypeen_GB
dc.subjectGlutathione Peroxidaseen_GB
dc.subjectPolymorphismen_GB
dc.subjectHumansen_GB
dc.subjectRisk Factorsen_GB
dc.subjectCase-Control Studiesen_GB
dc.subjectOdds Ratioen_GB
dc.subjectEuropeen_GB
dc.subject.meshAdult
dc.subject.meshCase-Control Studies
dc.subject.meshEurope
dc.subject.meshGenetic Predisposition to Disease
dc.subject.meshGenotype
dc.subject.meshGlutathione Peroxidase
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOdds Ratio
dc.subject.meshPolymorphism, Single Nucleotide
dc.subject.meshProstatic Neoplasms
dc.subject.meshRisk Factors
dc.subject.meshSelenium
dc.subject.meshSelenoproteins
dc.subject.meshSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
dc.titleEffects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.en
dc.typeArticleen
dc.identifier.journalCancer Epidemiology, Biomarkers & Preventionen_GB
html.description.abstractEvidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes.
html.description.abstractA case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).
html.description.abstractThe OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98).
html.description.abstractOur results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.
html.description.abstractThese findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies.


This item appears in the following Collection(s)

  • Articles
    Articles of researchers from ECNIS Network of Excellence

Show simple item record